Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
John Dormandy(St George's Hospital), B Charbonnel, D.J.A. Eckland, Erland Erdmann(University of Cologne), Massimo Massi‐Benedetti(University of Perugia), Ian K. Moules(Takeda (United Kingdom)), Allan M. Skene(Nottingham Biomedical Research Centre), Meng H. Tan(Eli Lilly (United States)), Pierre J. Lefèbvre(International Diabetes Federation), Gordon Murray(University of Edinburgh), Eberhard Standl(German Center for Diabetes Research), Robert G. Wilcox(University of Nottingham), Lars Wilhelmsen(University of Gothenburg), John Betteridge(University College London), Kåre I. Birkeland(University of Oslo), Alain Golay(University Hospital of Geneva), Robert J. Heine(Amsterdam UMC Location Vrije Universiteit Amsterdam), László Korányi, Markku Laakso(Kuopio University Hospital), Marián Mokáň(Comenius University Bratislava), Antanas Norkus, Valdis Pīrāgs, Toomas Podar(Competence Centre on Health Technologies (Estonia)), André Scheen(University of Liège), Werner A. Scherbaum(Deutsches Diabetes-Zentrum e.V.), Guntram Schernthaner(Rudolfinerhaus Hospital), Ole Schmitz(Aarhus University), J Skrha, Ulf Smith(University of Gothenburg), J Tatoń(Medical University of Warsaw)
Cited by 4,126Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis